Leadership Team

Johan Liwing has over 15 years’ experience from leading positions within the life sciences industry in Sweden as well as internationally. During his 13 years at Janssen (Johnson & Johnson), he held various positions in health economics, sales & marketing as well as observational research with increased responsibilities. In his last position at Janssen, as a Global Senior Director, he was responsible for developing the use of observational data. Johan Liwing has also worked for Roche as well as in other areas outside the life sciences industry, such as finance and engineering.

Hans Ericson is a Senior Finance professional with more than 20 years’ experience in international business and stock listed companies, with proven leadership in Controllership and Finance. He has had a number of leading positions primarily in Ericsson and Elekta, where he had the position as Group Controller for a long period of time. Hans has also been a consultant and have had assignments in various areas such as start-ups and large research organisations such as RISE.

Dr. Peter Hovstadius received his MD from Uppsala University in 1992, his specialist license in Clinical Pharmacology 2002 and his PhD in cancer drug development in 2005. During his career, he has held Medical Director positions at several global research-based pharmaceutical companies, including Roche, MSD and Novartis. He has a solid experience in drug development and oncology, being part of launching over 20 new medicines. Most recently he spent 8 years as Chief Scientific Officer at Novartis Nordics. Dr Hovstadius has a deep passion for precision medicine and bringing life-saving therapies to patients in need more quickly.

Dr. Maltais received her PhD. in immunobiology and tumor immunology from Karolinska Institutet in 2006. Since then, she has been leading R&D activities and strategies within several organizations and has also had roles within corporate and business development. Most recently, she comes from Chiesi Farmaceutici S.p.A., a global company that develops and markets therapeutic solutions within a number of different therapeutic areas. At Chiesi, she was Head of CMC, Biotech Research and Product Development, Global Rare Diseases.

Markus Thor is a business development executive with over 25 years of experience from the life science industry. In previous roles he was responsible for structuring, negotiating, and closing a range of global, strategic business agreements, including in- and out-licensing, acquisitions, and R&D collaborations. Previous positions include Vice President & Head of Business Development at Biovitrum AB, Chief Business Officer at Kancera AB and Senior Investment Advisor at Business Sweden. Thor received his MBA from Stockholm School of Economics and his MSc in Chemistry from the University of Umeå in Sweden and the University of Sussex, UK.